EUVIMEDOpdag EUVIMED
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen access · CC BY-NC 4.0

Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal

José Vera, André Gomes, Diana Póvoas, Diana Seixas, Fernando Maltez, Isabel Pedroto, Luís Maia, Margarida Mota, Maria João Vieira, Maria José Manata, Paula Ferreira, Sara Lino and 3 more

Acta Médica Portuguesa · 2024

DOI: 10.20344/amp.19178 ↗

At a glance

Beobachtungsstudie in Acta Médica Portuguesa, 2024. Written by José Vera and 14 co-authors. Institution: Centro Hospitalar Barreiro-Montijo. Barreiro. Portugal. Major MEDLINE topics: Benzimidazoles, Hepatitis C, Chronic, Quinoxalines, Antiviral Agents. Cited 2 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Information about pan-genotypic treatments for hepatitis in Portugal is scarce. We aimed to evaluate the effectiveness and safety of glecaprevir plus pibrentasvir (GLE/PIB) treatment for hepatitis C virus (HCV) infection in real-world clinical practice.

Methods

An observational prospective study was implemented in six hospitals with 121 adult HCV patients who initiated treatment with GLE/PIB between October 2018 and April 2019, according to clinical practice. Eligible patients had confirmed HCV infection genotype (GT) 1 to 6 and were either treatment-naïve or had experience with interferon-, ribavirin- or sofosbuvir-based regimens, with or without compensated cirrhosis. Baseline sociodemographic and safety data are described for the total population (N = 115). Effectiveness [sustained virologic response 12 weeks after treatment (SVR12)] and patient-reported outcomes are presented for the core population with sufficient follow-up data (n = 97).

Results

Most patients were male (83.5%), aged < 65 years (94.8%), with current or former alcohol consumption (77.3%), illicit drug use (72.6%), and HCV acquisition through intravenous drug use (62.0%). HIV co-infection occurred in 22.6% of patients. The prevalence of each GT was: GT1 51.3%, GT2 1.7%, GT3 30.4%, GT4 16.5%, and GT5.6 0%. Most patients were non-cirrhotic (80.9%) and treatment-naïve (93.8%). The SVR12 rates were 97.9% (95% CI: 92.8 - 99.4), and > 95% across cirrhosis status, GT, illicit drug use, alcohol consumption, and HCV treatment experience. The adverse event rate was 2.6%, and no patient discontinued treatment due to adverse events related to GLE/PIB.

Conclusion

Consistent with other real-world studies and clinical trials, treatment with GLE/PIB showed high effectiveness and tolerability overall and in difficult-to-treat subgroups (ClinicalTrials.gov: NCT03303599).

Subjects

MeSH terms (MEDLINE)

BenzimidazolesHepatitis C, ChronicQuinoxalinesAntiviral AgentsSulfonamidesPyrrolidinesDrug CombinationsHumansMaleFemaleMiddle AgedProspective StudiesAgedPortugalSustained Virologic ResponseTreatment OutcomeAdultLeucineHepacivirusLactams, MacrocyclicAminoisobutyric Acids

Author keywords

Chronic/drug therapyGenotypeGlecaprevirHepatitis CPibrentasvirPortugalTreatment Outcome

Substances

BenzimidazolesQuinoxalinesAntiviral AgentsSulfonamidesPyrrolidinesDrug CombinationsLeucineLactams, MacrocyclicAminoisobutyric Acids

Authors and institutions

  • Centro Hospitalar Barreiro-Montijo. Barreiro. Portugal.
  • Hospital Garcia de Orta. Almada. Portugal.
  • Centro Hospitalar Lisboa Central. Lisboa. Portugal.
  • Centro Hospitalar Universitário Porto. Porto. Portugal.
  • Centro Hospitalar Vila Nova de Gaia/Espinho. Vila Nova de Gaia. Portugal.
  • Centro Hospitalar Lisboa Norte. Lisboa. Portugal.

Cite

APA

Vera, J., Gomes, A., Póvoas, D., Seixas, D., Maltez, F., Pedroto, I., Maia, L., Mota, M., Vieira, M. J., Manata, M. J., Ferreira, P., Lino, S., Pereira Guedes, T., Barradas, V., & Marques, N. (2024). Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal. Acta Médica Portuguesa. https://doi.org/10.20344/amp.19178

Vancouver

Vera J, Gomes A, Póvoas D, Seixas D, Maltez F, Pedroto I, et al. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal. Acta Médica Portuguesa. 2024. doi:10.20344/amp.19178

BibTeX
@article{Vera2024,
  author = {Vera, José and Gomes, André and Póvoas, Diana and Seixas, Diana and Maltez, Fernando and Pedroto, Isabel and Maia, Luís and Mota, Margarida and Vieira, Maria João and Manata, Maria José and Ferreira, Paula and Lino, Sara and Pereira Guedes, Tiago and Barradas, Vânia and Marques, Nuno},
  title = {Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal},
  journal = {Acta Médica Portuguesa},
  year = {2024},
  doi = {10.20344/amp.19178}
}
Start for free →